{
    "xml": "<topic id=\"PHP4184\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/exenatide\" basename=\"exenatide\" title=\"EXENATIDE\">\n<title>EXENATIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1090\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/exenatide\">Exenatide</xref>\n</p>\n<data name=\"vtmid\">417734003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_798882457\" title=\"Glucagon-like peptide-1 receptor agonists\">Glucagon-like peptide-1 receptor agonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP48720\" outputclass=\"drugAction\" rev=\"1.11\" parent=\"/drugs/exenatide\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48680\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/drugs/exenatide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, or both, or with pioglitazone, or with both metformin and pioglitazone, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;micrograms twice daily for at least 1 month, then increased if necessary up to 10&#8239;micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart).</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection using modified-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8239;mg once weekly.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus in combination with basal insulin alone or with metformin or pioglitazone (or both)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;micrograms twice daily for at least 1 month, then increased if necessary up to 10&#8239;micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose of concomitant sulfonylurea may need to be reduced.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"pharmacokinetics\">\n<title>Pharmacokinetics</title>\n<p>Effect of <i>modified-release</i> exenatide injection (<i>Bydureon</i>\n<tm tmtype=\"reg\"/>) may persist for 10&#8239;weeks after discontinuation.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48743\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/exenatide\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Ketoacidosis</ph>; <ph outputclass=\"contraindication\">severe gastro-intestinal disease</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48768\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/exenatide\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Elderly</ph>; <ph outputclass=\"caution\">may cause weight loss greater than 1.5&#8239;kg weekly</ph>; <ph outputclass=\"caution\">pancreatitis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48665\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/exenatide\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n<p>Other drugs administered orally may need to be taken at least 1 hour before or 4 hours after exenatide injection, or taken with a meal when exenatide is not administered, to minimise possible interference with absorption.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48593\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/exenatide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain and distension</ph>; <ph outputclass=\"sideEffect\">agitation</ph>; <ph outputclass=\"sideEffect\">antibody formation</ph>; <ph outputclass=\"sideEffect\">asthenia</ph>; <ph outputclass=\"sideEffect\">decreased appetite</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disturbances</ph>; <ph outputclass=\"sideEffect\">gastro-oesophageal reflux disease</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypoglycaemia</ph>; <ph outputclass=\"sideEffect\">increased sweating</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>; <ph outputclass=\"sideEffect\">weight loss</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Pancreatitis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaphylactic reactions</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Angioedema</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">dehydration</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">eructation</ph>; <ph outputclass=\"sideEffect\">flatulence</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">renal impairment</ph>; <ph outputclass=\"sideEffect\">taste disturbance</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Pancreatitis</p>\n<p>Severe pancreatitis (sometimes fatal), including haemorrhagic or necrotising pancreatitis, has been reported rarely; discontinue permanently if pancreatitis is diagnosed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48753\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/exenatide\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Women of child-bearing age should use effective contraception during treatment with modified-release exenatide and for 12 weeks after discontinuation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48650\" outputclass=\"pregnancy\" parent=\"/drugs/exenatide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49231\" outputclass=\"breastFeeding\" parent=\"/drugs/exenatide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48627\" outputclass=\"renalImpairment\" parent=\"/drugs/exenatide\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>For <i>standard-release</i> injection, use with caution if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n<p>For <i>standard-release</i> injection, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n<p>For <i>modified-release</i> injection, avoid if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48642\" outputclass=\"patientAndCarerAdvice\" rev=\"1.18\" parent=\"/drugs/exenatide\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundMissedDoses\">\n<title>Missed doses</title>\n<sectiondiv>\n<p>If a dose of the immediate-release medicine is missed, continue with the next scheduled dose&#8212;do not administer <b>after</b> a meal. </p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients changing from standard-release to modified-release exenatide formulation may experience initial transient increase in blood glucose.</p>\n<p>Some oral medications should be taken at least 1 hour before or 4 hours after exenatide injection&#8212;consult product literature for details.</p>\n<p>Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek prompt medical attention if symptoms such as abdominal pain, nausea, and vomiting develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48514\" outputclass=\"nationalFunding\" rev=\"1.18\" parent=\"/drugs/exenatide\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA248</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Exenatide modified-release for the treatment of type 2 diabetes mellitis (February 2012)</p>\r\n<p>Modified-release exenatide in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended for the treatment of type 2 diabetes, only when glycaemic control is inadequate and the patient has:</p>\r\n<ul>\r\n<li>a body mass index (BMI) &#8805;35&#8239;kg/m<sup>2</sup> (in those of European descent, with appropriate adjustment for other ethnic groups) and weight-related psychological or medical problems, <i>or</i>\r\n</li>\r\n<li>a BMI &lt; 35&#8239;kg/m<sup>2</sup>, and insulin would be unacceptable for occupational reasons, or weight loss would benefit other significant obesity-related comorbidities.</li>\r\n</ul>\r\n<p>Treatment with modified-release exenatide in a triple therapy regimen should be continued only if HbA<sub>1c</sub> concentration is reduced by at least 1 percentage point and a weight loss of at least 3% is achieved within 6 months of starting treatment.</p>\r\n<p>Modified-release exenatide in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended only if:</p>\r\n<ul>\r\n<li>treatment with metformin or a sulphonylurea is contra- indicated or not tolerated, <i>and</i>\r\n</li>\r\n<li>treatment with thiazolidinediones and dipeptidylpeptidase-4 inhibitors is contra-indicated or not tolerated.</li>\r\n</ul>\r\n<p>Modified-release exenatide in a dual therapy regimen should be continued only if HbA<sub>1c</sub> concentration is reduced by at least 1 percentage point within 6 months of starting treatment.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA248\">www.nice.org.uk/TA248</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (June 2007) that standard-release exenatide (<i>Byetta</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin or sulfonylurea (or both), as an alternative to treatment with insulin in patients where treatment with metformin or sulfonylurea (or both) at maximally tolerated doses has been inadequate, and treatment with insulin would be the next option.</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has also advised (February 2011) that standard-release exenatide (<i>Byetta</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin and pioglitazone as a third-line pre-insulin treatment option.</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (December 2011) that modified-release exenatide (<i>Bydureon</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes as a third-line treatment option.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP4184-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/exenatide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76090\" title=\"Solution for injection\" namespace=\"/drugs/exenatide/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76100\" title=\"Powder and solvent for suspension for injection\" namespace=\"/drugs/exenatide/powder-and-solvent-for-suspension-for-injection\">Powder and solvent for suspension for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"6\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1090\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/exenatide\" title=\"Exenatide\" count=\"1\" rel=\"link\">Exenatide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76090\" namespace=\"/drugs/exenatide/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76100\" namespace=\"/drugs/exenatide/powder-and-solvent-for-suspension-for-injection\" title=\"Powder and solvent for suspension for injection\" count=\"1\" rel=\"link\">Powder and solvent for suspension for injection</xref>\n</links>\n</topic>",
    "id": "PHP4184",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/exenatide",
    "basename": "exenatide",
    "title": "EXENATIDE",
    "interactants": [
        {
            "id": "bnf_int_1090",
            "label": "Exenatide"
        }
    ],
    "vtmid": "417734003",
    "drugClassification": [
        "Glucagon-like peptide-1 receptor agonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.",
                "html": "<p>Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, or both, or with pioglitazone, or with both metformin and pioglitazone, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination",
                        "html": "Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, or both, or with pioglitazone, or with both metformin and pioglitazone, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection using modified-release medicines"
                    ],
                    "textContent": "By subcutaneous injection using modified-release medicines",
                    "html": "By subcutaneous injection using modified-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 micrograms twice daily for at least 1 month, then increased if necessary up to 10 micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart).",
                        "html": "<p>Initially 5&#8239;micrograms twice daily for at least 1 month, then increased if necessary up to 10&#8239;micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart).</p>"
                    },
                    {
                        "textContent": "2 mg once weekly.",
                        "html": "<p>2&#8239;mg once weekly.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus in combination with basal insulin alone or with metformin or pioglitazone (or both)",
                        "html": "Type 2 diabetes mellitus in combination with basal insulin alone or with metformin or pioglitazone (or both)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection using immediate-release medicines"
                    ],
                    "textContent": "By subcutaneous injection using immediate-release medicines",
                    "html": "By subcutaneous injection using immediate-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 micrograms twice daily for at least 1 month, then increased if necessary up to 10 micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart).",
                        "html": "<p>Initially 5&#8239;micrograms twice daily for at least 1 month, then increased if necessary up to 10&#8239;micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart).</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose of concomitant sulfonylurea may need to be reduced.",
                "html": "<p>Dose of concomitant sulfonylurea may need to be reduced.</p>"
            }
        ],
        "pharmacokinetics": [
            {
                "type": "pharmacokinetics",
                "title": "Pharmacokinetics",
                "textContent": "Effect of modified-release exenatide injection (Bydureon ) may persist for 10 weeks after discontinuation.",
                "html": "<p>Effect of <i>modified-release</i> exenatide injection (<i>Bydureon</i>\n<tm tmtype=\"reg\"/>) may persist for 10&#8239;weeks after discontinuation.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Ketoacidosis",
                "html": "Ketoacidosis"
            },
            {
                "type": "contraindications",
                "textContent": "severe gastro-intestinal disease",
                "html": "severe gastro-intestinal disease"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Elderly",
                "html": "Elderly"
            },
            {
                "type": "cautions",
                "textContent": "may cause weight loss greater than 1.5 kg weekly",
                "html": "may cause weight loss greater than 1.5&#8239;kg weekly"
            },
            {
                "type": "cautions",
                "textContent": "pancreatitis",
                "html": "pancreatitis"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).\n\nOther drugs administered orally may need to be taken at least 1 hour before or 4 hours after exenatide injection, or taken with a meal when exenatide is not administered, to minimise possible interference with absorption.",
                "html": "<p>Appendix 1 (antidiabetics).</p><p>Other drugs administered orally may need to be taken at least 1 hour before or 4 hours after exenatide injection, or taken with a meal when exenatide is not administered, to minimise possible interference with absorption.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain and distension",
                        "html": "Abdominal pain and distension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "agitation",
                        "html": "agitation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "antibody formation",
                        "html": "antibody formation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "asthenia",
                        "html": "asthenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "decreased appetite",
                        "html": "decreased appetite",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-intestinal disturbances",
                        "html": "gastro-intestinal disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-oesophageal reflux disease",
                        "html": "gastro-oesophageal reflux disease",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypoglycaemia",
                        "html": "hypoglycaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "increased sweating",
                        "html": "increased sweating",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight loss",
                        "html": "weight loss",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Pancreatitis",
                        "html": "Pancreatitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Anaphylactic reactions",
                        "html": "Anaphylactic reactions",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Angioedema",
                        "html": "Angioedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dehydration",
                        "html": "dehydration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "eructation",
                        "html": "eructation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "flatulence",
                        "html": "flatulence",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "renal impairment",
                        "html": "renal impairment",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "taste disturbance",
                        "html": "taste disturbance",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Pancreatitis",
                "textContent": "Severe pancreatitis (sometimes fatal), including haemorrhagic or necrotising pancreatitis, has been reported rarely; discontinue permanently if pancreatitis is diagnosed.",
                "html": "<p>Severe pancreatitis (sometimes fatal), including haemorrhagic or necrotising pancreatitis, has been reported rarely; discontinue permanently if pancreatitis is diagnosed.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Women of child-bearing age should use effective contraception during treatment with modified-release exenatide and for 12 weeks after discontinuation.",
                "html": "<p>Women of child-bearing age should use effective contraception during treatment with modified-release exenatide and for 12 weeks after discontinuation.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;toxicity in animal studies.",
                "html": "<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;no information available.",
                "html": "<p>Avoid&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "For standard-release injection, use with caution if eGFR 30&#8211;50 mL/minute/1.73 m2.\n\nFor standard-release injection, avoid if eGFR less than 30 mL/minute/1.73 m2.\n\nFor modified-release injection, avoid if eGFR less than 50 mL/minute/1.73 m2.",
                "html": "<p>For <i>standard-release</i> injection, use with caution if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>For <i>standard-release</i> injection, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>For <i>modified-release</i> injection, avoid if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundMissedDoses": [
            {
                "type": "adviceAroundMissedDoses",
                "textContent": "If a dose of the immediate-release medicine is missed, continue with the next scheduled dose&#8212;do not administer after a meal.",
                "html": "<p>If a dose of the immediate-release medicine is missed, continue with the next scheduled dose&#8212;do not administer <b>after</b> a meal. </p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients changing from standard-release to modified-release exenatide formulation may experience initial transient increase in blood glucose.\n\nSome oral medications should be taken at least 1 hour before or 4 hours after exenatide injection&#8212;consult product literature for details.\n\nPatients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek prompt medical attention if symptoms such as abdominal pain, nausea, and vomiting develop.",
                "html": "<p>Patients changing from standard-release to modified-release exenatide formulation may experience initial transient increase in blood glucose.</p><p>Some oral medications should be taken at least 1 hour before or 4 hours after exenatide injection&#8212;consult product literature for details.</p><p>Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek prompt medical attention if symptoms such as abdominal pain, nausea, and vomiting develop.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA248",
                        "label": "www.nice.org.uk/TA248"
                    }
                ],
                "fundingIdentifier": "NICE TA248",
                "textContent": "Exenatide modified-release for the treatment of type 2 diabetes mellitis (February 2012) Modified-release exenatide in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended for the treatment of type 2 diabetes, only when glycaemic control is inadequate and the patient has: a body mass index (BMI) &#8805;35 kg/m2 (in those of European descent, with appropriate adjustment for other ethnic groups) and weight-related psychological or medical problems, or a BMI < 35 kg/m2, and insulin would be unacceptable for occupational reasons, or weight loss would benefit other significant obesity-related comorbidities. Treatment with modified-release exenatide in a triple therapy regimen should be continued only if HbA1c concentration is reduced by at least 1 percentage point and a weight loss of at least 3% is achieved within 6 months of starting treatment. Modified-release exenatide in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended only if: treatment with metformin or a sulphonylurea is contra- indicated or not tolerated, and treatment with thiazolidinediones and dipeptidylpeptidase-4 inhibitors is contra-indicated or not tolerated. Modified-release exenatide in a dual therapy regimen should be continued only if HbA1c concentration is reduced by at least 1 percentage point within 6 months of starting treatment.\n\nwww.nice.org.uk/TA248",
                "html": "<p outputclass=\"title\">Exenatide modified-release for the treatment of type 2 diabetes mellitis (February 2012)</p> <p>Modified-release exenatide in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended for the treatment of type 2 diabetes, only when glycaemic control is inadequate and the patient has:</p> <ul> <li>a body mass index (BMI) &#8805;35&#8239;kg/m<sup>2</sup> (in those of European descent, with appropriate adjustment for other ethnic groups) and weight-related psychological or medical problems, <i>or</i> </li> <li>a BMI &lt; 35&#8239;kg/m<sup>2</sup>, and insulin would be unacceptable for occupational reasons, or weight loss would benefit other significant obesity-related comorbidities.</li> </ul> <p>Treatment with modified-release exenatide in a triple therapy regimen should be continued only if HbA<sub>1c</sub> concentration is reduced by at least 1 percentage point and a weight loss of at least 3% is achieved within 6 months of starting treatment.</p> <p>Modified-release exenatide in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended only if:</p> <ul> <li>treatment with metformin or a sulphonylurea is contra- indicated or not tolerated, <i>and</i> </li> <li>treatment with thiazolidinediones and dipeptidylpeptidase-4 inhibitors is contra-indicated or not tolerated.</li> </ul> <p>Modified-release exenatide in a dual therapy regimen should be continued only if HbA<sub>1c</sub> concentration is reduced by at least 1 percentage point within 6 months of starting treatment.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA248\">www.nice.org.uk/TA248</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76090",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76100",
                "label": "Powder and solvent for suspension for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1090",
                "label": "Exenatide",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76090",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76100",
                "label": "Powder and solvent for suspension for injection",
                "type": "medicinalForm"
            }
        ]
    }
}